Last reviewed · How we verify
NCT05633706
Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
trial testing fluid biopsy capsule in Irritable Bowel Syndrome in 300 participants. Currently enrolling.
6 June 2025
Quick facts
| Lead sponsor | Nimble Science Ltd. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 9 January 2023 |
| Primary completion | 6 June 2025 |
| Estimated completion | 6 June 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- fluid biopsy capsule
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
- Crohn Disease — all drugs for Crohn Disease →
- Celiac Disease — all drugs for Celiac Disease →
- Ulcerative Colitis — all drugs for Ulcerative Colitis →
Sponsor
Nimble Science Ltd. — full company profile →
Who can join
Adults 18 to 80, any sex, with Irritable Bowel Syndrome or Crohn Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Glycaemic sugar metabolism and the gut microbiota: past, present and future.
Westerbeke FHM, Attaye I, Rios-Morales M, Nieuwdorp M. · · 2025 · cited 3× · PMID 39359099 · DOI 10.1111/febs.17293
Verify or expand the search:
- PubMed search for NCT05633706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other Nimble Science Ltd. trials
Trials by the same sponsor.
- NCT06394687 — The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule · NA · active not recruiting
- NCT05844826 — Evaluation of the Microbiome in Multiple Sclerosis · NA · terminated
- NCT04489329 — Dietary Intervention Detection in the Small Intestine · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05633706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nimble Science Ltd.
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05633706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing